Neu-REFIX Beta glucan receives rare pediatric disease and orphan drug designations from the US FDA for treatment of Duchenne Muscular Dystrophy
Rare diseases research provides insights into auto-immune diseases and Psoriasis.
Neu REFIX Beta glucan, made in Japan has received both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (US FDA) for treatment of Duchenne muscular Dystrophy (DMD). These designations would help take the progress in pre-clinical and clinical studies conducted in Japan and India to clinical trials in the USA, for approval by FDA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240920153092/en/
The parable of the lost sheep mirrors our journey to find a solution for Duchenne Muscular Dystrophy (DMD), a rare disease. Our global interdisciplinary team is fortunate to have been gifted with Neu REFIX, whose hidden potentials of beneficial immune modulation, we unravelled by extensive preclinical and clinical studies. This gives hope to DMD patients for its potentials in improving their quality of life by halting the disease progress. Like the shepherd when he found the lost sheep, our joy knew no bounds, when we got encouraging outcome in DMD research. Now on receiving orphan drug and rare paediatric disease designations from US FDA, while it’s time to rejoice, we have miles to go until it reaches every deserving patient after an approval, the final goal. We are open to collaborate with likeminded institutes to reach the goal. Further insights have revealed the potentials of Neu REFIX in Psoriasis, auto-immune diseases and in Multiple Sclerosis by gut microbiome reconstitution. (Graphic: Business Wire)
The Neu-REFIX Beta 1,3-1,6 glucan, is an exo-polysaccharide produced by N-163 strain of Aureobasidium Pullulans, available as an orally consumable, allergen-free, food supplement, that has proven to be safe, with the following potentials in DMD:
- Stand-alone efficacy in reducing skeletal muscle inflammation and fibrosis in mdx mice
- Enhancement of muscle regeneration in mdx mice in a duration of 45-days
- Decline in fatigue score in pre-clinical study
- Clinically safe as an adjuvant along with varying regimens of standard-of-care treatment
- Efficacy of improvement in plasma dystrophin in a clinical study of 45-days duration
- Halting of disease progress in a clinical trial of six months, safely
- Beneficial reconstitution of gut microbiome in patients with DMD
- Clinical improvement in patients with LGMD
- Reduction of myocardial fibrosis in mdx mice
The research findings of the journey started in 2009 have been published in peer-reviewed journals and conferences including the Asian and Oceanian Myology Center- Japan Muscle Society joint conference, AOMC-JMS 2024.
DMD is a rare genetic disease affecting 1 in 5000 male births with close to 50000 patients in the USA. The anti-inflammatory potentials of Neu-REFIX documented in the rare disease of DMD have paved ways to expand further research to include auto-immune diseases, rare disease like Multiple Sclerosis and also common skin diseases like Psoriasis Vulgaris as a disease modifying adjuvant.
Neu-REFIX is a food supplement produced in Japan and available commercially since 2018; A food additive as per Japanese standards. It’s not a drug or remedy to any illness; nor a diagnostic or disease preventing agent. Research outputs are not to be construed as medical advice. The information is propagated to gain relevant support from organizations with synergy to undertake clinical trials and obtain approvals from regulatory agencies. The RPDD and ODD designations are not approvals but are considered as a validation of our approach that have several advantages of market exclusivity, access to grants and research support as well as a fast-track progress.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240920153092/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canoga Perkins Announces Breakthrough Private 5G Transport Solution Enabling Time Sensitive Networking (TSN)19.2.2025 07:00:00 CET | Press release
SyncMetra® 100 is a software-defined, IT-operated 5G network transport solution that guarantees ultra-low latency, deterministic wireless communications for industrial automation, enterprise AI, and AR/VR applications. Network connectivity solutions provider, Canoga Perkins today announced that it has begun shipping evaluation units for its SyncMetra 100 transport solution, purpose-built to simplify the deployment, configuration, management, and expansion of low latency private 5G networks for industrial automation including TSN, enterprise AI, and AR/VR applications. In addition, the company announced its upcoming presence at Mobile World Congress in Barcelona, March 3-6 (Hall 7 Stand 7C3Ex) and at Hannover Messe, March 31-April 4 where it will be demonstrating the SyncMetra solution. "As advancements in AI, automation and IoT accelerate the proliferation of use cases, the market has been constrained to deploy deterministic wireless networks,” said Malik Arshad, President of Canoga Pe
Celltrion Expands Biosimilar Portfolio in the European Union Following European Commission Approval of Two Biosimilars19.2.2025 03:57:00 CET | Press release
Celltrion gains simultaneous regulatory approval of two monoclonal antibody biosimilars across three treatments – Eydenzelt® (aflibercept), Stoboclo® and Osenvelt® (denosumab) in the EU marketEuropean Commission approval based on totality of evidence including extensive comparative analytical, pharmacokinetic and clinical dataThe company expands its biosimilar portfolio to 11 in 2025 as planned, further strengthening its commitment to a portfolio of 22 drugs by 2030 Celltrion today announced that the European Commission (EC) has granted marketing authorization for three products across two biosimilars: Eydenzelt® (CT-P42, aflibercept), a biosimilar to Eylea® to treat multiple retinal disorders, including neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO, branch RVO or central RVO), diabetic macular edema (DME) and myopic choroidal neovascularisation (myopic CNV); and Stoboclo® and Osenvelt® (CT-P41, denosumab), biosimilars ref
IFF Reports Fourth Quarter and Full Year 2024 Results18.2.2025 22:49:00 CET | Press release
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2024. Management Commentary "IFF delivered a solid performance in 2024, reflecting the hard work and dedication of our global team,” said CEO Erik Fyrwald. "Their commitment to serving our customers with industry-leading innovation drove strong top and bottom-line financial results. I’m pleased with the significant progress we’ve made over the past year yet believe that we still have more work to do to realize IFF's full potential. In 2025, we'll strategically increase our investment in R&D, commercial, capacity and technology as we aim to continue to strengthen IFF. Recognizing ongoing macroeconomic uncertainties, we remain confident in our strategy and our ability to navigate challenges as we continue to create long-term value for all shareholders." Full year 2024 Consolidated Financial Results Reported net sales for the full year were $11.48 billion,
SES Market Update in Context of Moody’s Ratings Press Release18.2.2025 18:10:00 CET | Press release
SES S.A. has taken note of Moody’s Ratings Press Release today with regards to SES and is providing a market update ahead of its Full Year 2024 financial results announcement on 26 February 2025. SES expects Full Year 2024 Results(1) to be better-than-expected with Revenue at the top end of the financial outlook range (€1,940-2,000 million)(2) and Adjusted EBITDA above the outlook range (€950-1,000 million)(2). The proposed acquisition of Intelsat is on track to close during H2 2025. SES expects to reconfirm all financial targets for the combined company (pre-IRIS2) published in the transaction announcement in April 2024, including low- to mid-single digit average annual growth in Revenue for 2024-2028E, mid-single digit average annual growth in Adjusted EBITDA for 2024-2028E, and strong Free Cash Flow generation. SES remains committed to maintaining Investment Grade metrics. SES management looks forward to announcing its Full Year 2024 Results and discussing these, as well as its view
Planview Acquires Sciforma, Expanding Global Leadership in Portfolio Management Solutions18.2.2025 18:00:00 CET | Press release
Combined offerings support organizations at every Project Portfolio Management maturity level Planview®, the leading platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced it has completed its acquisition of Sciforma, a prominent provider of Project Portfolio Management (PPM) and Product Development solutions. This strategic acquisition further solidifies Planview's position as the undisputed leader in enterprise portfolio management, bringing market-leading solutions to organizations at every PPM maturity level. "By acquiring Sciforma, we're strengthening our commitment to portfolio management practitioners worldwide," said Razat Gaurav, CEO of Planview. "Together, we're building the world's largest community of portfolio and product development professionals, delivering enterprise solutions that address their most critical challenges. No one in the market is better equipped to guide organizations through every stage of their portfolio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom